974-41-4

Basic information

• Product Name: 8-benzyl-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one
• Synonyms: 8-benzyl-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one;8-BENZYL-4-KETO-1-PHENYL-1,3,8-TRIAZASPIRO[4,5]DECANE;8-Benzyl-4-oxo-phenyl-1,3,8-triazaspiro[4, 5]decane, 99%;1-phenyl-8-(phenylmethyl)-1,3,8-triazaspiro[4.5]decan-4-one;8-Benzyl-1,3,8-triazaspiro[4.5]decane-4-one;NSC 664996;NSC 73400;R 5079
• CAS NO: 974-41-4
• Molecular Formula: C₂₀H₂₃N₃O
• Molecular Weight: 321.41612
• EINECS: 213-549-8
• Mol File: 974-41-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 232-238℃
• Boiling Point: 538℃
• Flash Point: 279℃
• Appearance: /
• Density: 1.22
• Vapor Pressure: 1.2E-11mmHg at 25°C
• Refractive Index: 1.655
• CAS DataBase Reference: 8-benzyl-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-benzyl-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one(974-41-4)
• EPA Substance Registry System: 8-benzyl-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one(974-41-4)

Safety Data

• Hazardous Substances Data: 974-41-4(Hazardous Substances Data)

Usage

General Description

8-benzyl-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one is a chemical compound with a spiro ring structure and a carbonyl group. It belongs to the class of heterocyclic compounds and has potential applications in pharmaceuticals. The benzyl and phenyl groups in the molecule enhance its lipophilicity and can influence its biological activity. This chemical has the potential for use in drug development and research due to its unique molecular structure and potential pharmacological properties. Its spiro ring structure and functional groups make it an interesting compound for further investigation and potential application in the pharmaceutical industry.

InChI:InChI=1/C20H23N3O/c24-19-20(23(16-21-19)18-9-5-2-6-10-18)11-13-22(14-12-20)15-17-7-3-1-4-8-17/h1-10H,11-16H2,(H,21,24)

Upstream product

• 1096-03-3 1-benzyl-4-phenylaminopiperidine-4-carboxylic acid amide 
• 62-53-3 aniline 
• 968-86-5 1-benzyl-4-(phenylamino)piperidine-4-carbonitrile 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 974-42-5 1-(phenylmethyl)-4,4-(2-phenyl-2,4-diaza-4-oxo-cyclopentane)piperidine 
• 77287-34-4 formamide 
• 100-52-7 benzaldehyde 
• 1021-25-6 1-Phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 

Downstream Products

• 1021-25-6 1-Phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 

Relevant articles and documents

Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors

Aiming to develop novel Type-I1/2 inhibitors of ALK to overcome extensive resistance mutations, especially the L1196M mutation surrounding the ATP pocket, two series of 2-arylaminopyrimidine derivatives (11a-f and 22a-t) were designed based on scaffold hopping. The extensive structural elaboration discovered compound 22o which possessed excellent IC50 values of 0.06 and 0.23 μM against ALK-positive Karpas299 and H2228 cell lines, respectively. Meanwhile, 22o displayed encouraging inhibitory potency in the ALKWT (2.5 nM) and ALKL1196M (6.5 nM) enzymatic assays. Furthermore, the AO/EB and Hoechst 33258 assays illustrated 22o could induce cell apoptosis in a dose-dependent manner. Eventually, the molecular docking of 22o with ALK clearly presented the vital interactions within the active site, which was in accordance with Type-I1/2 inhibitor binding mode.

Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction

Recent cardiology research studies have reported the role, function, and structure of the mitochondrial permeability transition pore (mPTP) and have shown that its opening plays a key role in the progression of myocardial cell death secondary to reperfusion. In this manuscript, we validated a new pharmacological approach as an adjunct to reperfusion in myocardial infarction (MI) treatment and describe the discovery, optimization, and structure-activity relationship (SAR) studies of the first small-molecule mPTP opening inhibitors based on a 1,3,8-triazaspiro[4.5]decane scaffold that targets the c subunit of the F1/FO-ATP synthase complex. We identified three potential compounds with good mPTP inhibitory activity and beneficial effects in a model of MI, including a decreased apoptotic rate in the whole heart and overall improvement of cardiac function upon administration during reperfusion. The selected compounds did not show off-target effects at the cellular and mitochondrial levels. Moreover, the compounds preserved the mitochondrial ATP content despite interacting with the ATP synthase complex.

In search of novel agents for therapy of tropical diseases and human immunodeficiency virus

Malaria, sleeping sickness, Chagas' disease, Aleppo boil, and AIDS are among the tropical diseases causing millions of infections and cases of deaths per year because only inefficient chemotherapy is available. Since the targeting of the enzymes of the polyamine pathway may provide novel therapy options, we aimed to inhibit the deoxyhypusine hydroxylase, which is an important step in the biosynthesis of the eukaryotic initiation factor 5A. In order to identify new lead compounds, piperidines were produced and biologically evaluated. The 3,5-diethyl piperidone-3,5-dicarboxylates 11 and 13 substituted with 4-nitrophenyl rings in the 2 and 6 positions were found to be active against Trypanosoma brucei brucei and Plasmodium falciparum combined with low cytotoxicity against macrophages. The corresponding monocarboxylates are only highly active against the T. brucei brucei. The piperidine oximether 53 demonstrated the highest plasmodicidal activity. Moreover, compounds 11 and 53 were also able to inhibit replication of HIV-1.